Filter by
Filter by
Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer
This study used clinicopathologic factors to match 25 patients with OPC who received IMPT and 25 patients with OPC treated with IMRT. Process maps were created...
Intensity Modulated Proton Beam Therapy versus Volumetric Modulated Arc Therapy for Patients with Nasopharyngeal Cancer: A Propensity Score-Matched Study
This study conducted a retrospective propensity score matching analysis (1:1) of 80 NPC patients treated with IMPT and VMAT. At a median follow-up time of 24.1...
Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016
Based on the SEER database, this study reported that for Medicare beneficiaries with a first-time diagnosis of prostate cancer, the utilization of IMRT, proton...
Dose distribution of intensity-modulated proton therapy with and without a multi-leaf collimator for the treatment of maxillary sinus cancer: a comparative effectiveness study.
Using collimation can sharpen the penumbra towards surrounding normal tissue in the low energy region of the proton beam, this study from Japan thus examined...
Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer.
Published in JCO (Journal of Clinical Oncology), this randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between PBT and...
Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer.
This study compared 46 IMPT and 259 VMAT patients acute toxicities and reported that IMPT was associated with lower PEG-tube placement (p = 0.001) and less...
The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation
A cohort of 30 patients was retrospectively selected as "at-risk" of dose de-escalation due to the proximity of the target volumes to dose-limiting healthy...
TORPEdO - Phase III Trial of IMPT Vs IMRT for Multi-toxicity Reduction in Oropharyngeal Cancer.
This is the UK's first proton clinical trial. Published in the Clinical Oncology, this editorial provided the rational and the plan of the trial. It is a...